Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

New Drug Could Double Survival for Eligible Patients with Pancreatic Cancer

1 August 2026 · By · Wire by Fusion42

Published

1 August 2026

Topic

regulatory

◆ Sectors

Drug Discovery

◆ Geography

United States

◆ Source

Read at newswise.com →

◆ Verified

Fusion42 · 2 August 2026 · Fusion42 review

Daraxonrasib, a new RAS(ON) inhibitor drug for metastatic pancreatic ductal adenocarcinoma (PDAC), has doubled median survival in clinical trials and is currently available through expanded access programs pending FDA approval in the United States.

This Wire brief sits within Fusion42's coverage of Drug Discovery.

◆ ◆ The Wire takeaway

Pancreatic cancer drug daraxonrasib moving through FDA approval opens a new treatment frontier. You in drug development or oncology need to act on trial data credibility or updated market access pathways now.

◆ Coverage

1 source · 1 Aug 2026

◆ Related on Wire

◆ Topics

Drug Discoverypancreatic-cancerdrug-approvalclinical-trialsras-inhibitorexpanded-accessoncology